| CCL3, also known as macrophage inflammatory protein-1α (MIP-1α), is a CC chemokine produced mainly by activated macrophages, T cells and other myeloid-lineage cells that functions as a potent chemoattractant and activation signal for leukocytes, integrating inflammatory cues with chemokine receptor signaling to shape innate and adaptive immune responses. The protein belongs to the CC chemokine family and adopts the typical compact chemokine fold with an N‑terminal region that engages G protein–coupled receptors and a conserved cysteine motif that stabilizes its structure, allowing high-affinity binding to CCR1 and CCR5 on target cells. Upon binding to CCR1 or CCR5, CCL3 triggers Gαi‑coupled signaling that activates downstream ERK1/2, JNK and p38 MAPK pathways, increases intracellular calcium and reorganizes the actin cytoskeleton, resulting in directional chemotaxis of monocytes, neutrophils, NK cells and subsets of T lymphocytes toward inflammatory sites. In GM‑CSF–primed neutrophils, short-term exposure induces CCR1 and CCR5 expression and renders neutrophils responsive to CCL3, where CCR5-dependent ERK1/2 activation drives in vitro migration and acquisition of locomotory behavior, demonstrating a context in which priming cytokines license CCL3 responsiveness through receptor and MAPK pathway modulation. CCL3 also upregulates CCR1/CCR5 and activates JNK/p38 MAPK signaling in pancreatic acinar cells during acute pancreatitis, leading to increased TNF‑α and IL‑6 production, reinforcing inflammatory cascades and supporting its role as both chemotactic and a proinflammatory effector. In rheumatoid arthritis, CCL3 is highly expressed in synovial tissue and fluid, where it promotes leukocyte recruitment into the joint, enhances secretion of other inflammatory mediators, supports angiogenesis and contributes to bone and cartilage destruction, positioning CCL3 as a key mediator of joint inflammation and structural damage. CCL3 also acts beyond classical inflammation: in the hippocampus, experimental elevation of CCL3 impairs basal synaptic transmission at Schaffer collateral–CA1 synapses and selectively disrupts long-term potentiation without affecting NMDA receptor potentials, effects reversed by the CCR5 antagonist maraviroc, indicating that CCL3–CCR5 signaling serves as a neuromodulatory mechanism that can negatively regulate synaptic plasticity and memory. In HIV infection, CCL3 is one of the natural ligands for CCR5, the major coreceptor used by R5-tropic HIV‑1; its binding to CCR5 competitively blocks gp120 engagement and inhibits viral entry into CD4+ T cells, and gp120-specific CD4+ T cells that secrete CCR5 ligands, including CCL3, can suppress HIV infection of autologous cells, illustrating a protective facet of CCL3–CCR5 interactions in antiviral immunity. However, serum CCL3 levels do not correlate reliably with HIV disease stage or treatment response, so its systemic concentration is not a robust biomarker even though local CCR5 ligand production is mechanistically important for viral restriction. In B-cell malignancies such as chronic lymphocytic leukemia, B‑cell receptor engagement induces CCL3 secretion by CLL cells, and elevated plasma CCL3 associates with more aggressive disease and enhanced microenvironmental interactions, making it a useful surrogate for ongoing BCR signaling and a candidate marker for disease progression. |
